Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Immunome (IMNM) EBITDA Margin (2023 - 2025)

Historic EBITDA Margin for Immunome (IMNM) over the last 3 years, with Q2 2025 value amounting to 1157.61%.

  • Immunome's EBITDA Margin rose 5348200.0% to 1157.61% in Q2 2025 from the same period last year, while for Sep 2025 it was 2419.9%, marking a year-over-year increase of 7145000.0%. This contributed to the annual value of 3382.37% for FY2024, which is 26010200.0% down from last year.
  • Immunome's EBITDA Margin amounted to 1157.61% in Q2 2025, which was up 5348200.0% from 1525.5% recorded in Q1 2025.
  • In the past 5 years, Immunome's EBITDA Margin registered a high of 129.96% during Q3 2023, and its lowest value of 12857.05% during Q1 2024.
  • Over the past 3 years, Immunome's median EBITDA Margin value was 1608.96% (recorded in 2025), while the average stood at 2492.75%.
  • As far as peak fluctuations go, Immunome's EBITDA Margin tumbled by -126679200bps in 2024, and later skyrocketed by 113315500bps in 2025.
  • Over the past 3 years, Immunome's EBITDA Margin (Quarter) stood at 2473.94% in 2023, then decreased by -22bps to 3030.31% in 2024, then skyrocketed by 62bps to 1157.61% in 2025.
  • Its last three reported values are 1157.61% in Q2 2025, 1525.5% for Q1 2025, and 3030.31% during Q4 2024.